www.imbruvica.com Open in urlscan Pro
2600:9000:26db:6a00:1e:46ba:d300:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Learn how AbbVie could help you save on IMBRUVICA®. Call 1-866-IMBRUVICA or
click to learn more >

Choose Indication
Affording IMBRUVICA®
Dosing Guide
Patient Support
& Savings
Patient Support Enrollment
Important Side
Effect Information
Prescribing Information
Full Prescribing Information (English)
Full Prescribing Information (En Español)
Español
Healthcare Professionals
CLL/SLLAdults with Chronic Lymphocytic Leukemia/Small Lymphocytic
LymphomaWMAdults with Waldenström's MacroglobulinemiacGVHDPreviously Treated
Chronic Graft Versus Host Disease in Adults and Children


IMBRUVICA® HAS HELPED MANY ADULTS WITH CLL/SLL LIVE LONGER

In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib)
died versus 16% taking a chemotherapy (chlorambucil), after 28 months of
follow-up.1*

Here’s to more time together and the opportunity to keep doing what you love.

Here’s to the life in your years


HERE’S TO SAVING ON IMBRUVICA®

You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card.
Subject to eligibility; restrictions apply.†

Enroll Now

Receive one-on-one support plus financial and educational resources to help
start and stay on track with IMBRUVICA®‡

Explore Support Options


IMBRUVICA® IS APPROVED FOR MULTIPLE USES. CHOOSE FROM BELOW:

CLL/SLLAdults with Chronic Lymphocytic Leukemia/Small Lymphocytic
LymphomaWMAdults with Waldenström's MacroglobulinemiacGVHDPreviously Treated
Chronic Graft Versus Host Disease in Adults and Children

*In a clinical study of 269 people aged 65 and older with chronic lymphocytic
leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not been treated
before, people who took IMBRUVICA® had a 56% lower risk of death compared to
those taking a chemotherapy (chlorambucil). With a median follow-up of
approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a
chemotherapy.


A TREATMENT OPTION THAT ISN'T CHEMOTHERAPY

IMBRUVICA® is an oral, once-daily medicine that works differently from
chemotherapy.

Learn More About How IMBRUVICA® Works


COVERAGE AND COST QUESTIONS?

Understand your insurance coverage and potential financial support options.

Explore Coverage and Cost Options


DISCOVER PERSONALIZED ONE-ON-ONE SUPPORT

Get support when you need it with help from IMBRUVICA® By Your Side Ambassadors
and communications.‡

Explore Support Options


LEARN FROM A PATIENT

Real CLL patients tell personal stories about their experience with IMBRUVICA®.

View Patient Videos

†Eligibility: Available to patients with commercial insurance coverage for
IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance
program is not available to patients receiving prescription reimbursement under
any federal, state, or government-funded insurance programs (for example,
Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE,
Department of Defense, or Veterans Affairs programs) or where prohibited by law.
Offer subject to change or termination without notice. Restrictions, including
monthly maximums, may apply. This is not health insurance. For full Terms and
Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call
1-888-968-7743 for additional information. For information on how we collect and
process your personal data, including the categories we collect, purposes for
their collection, and disclosures to third parties, visit
https://www.pharmacyclics.com/privacy-notice.html#info_pcp.

‡IMBRUVICA® By Your Side patient support program is not intended to provide
medical advice, replace prescribed treatment plans, or provide treatment or case
management services. Patients are advised to talk to their healthcare provider
and treatment team about any medical decisions and concerns they may have. By
Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics
LLC, an AbbVie Company, and do not work under the direction of your healthcare
professional (HCP) or give medical advice. They are trained to direct patients
to their HCP for treatment-related advice, including further referrals.

Reference: 1. IMBRUVICA® (ibrutinib) Prescribing Information.

IMPORTANT SIDE EFFECT INFORMATION

USES

Before taking IMBRUVICA®, tell your healthcare provider about all of your
medical conditions, including if you:

 * have had recent surgery or plan to have surgery. Your healthcare provider may
   stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
 * have bleeding problems or are taking a blood thinner medicine.
 * have an infection.
 * have or had heart rhythm problems, smoke, or have a medical condition that
   increases your risk of heart disease, such as high blood pressure, high
   cholesterol, or diabetes.
 * have liver problems.
 * are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn
   baby. If you are able to become pregnant, your healthcare provider will do a
   pregnancy test before starting treatment with IMBRUVICA®. Tell your
   healthcare provider if you are pregnant or think you may be pregnant during
   treatment with IMBRUVICA®.
   * Females who are able to become pregnant should use effective birth control
     (contraception) during treatment with IMBRUVICA® and for 1 month after the
     last dose.
   * Males with female partners who are able to become pregnant should use
     effective birth control, such as condoms, during treatment with IMBRUVICA®
     and for 1 month after the last dose.
 * are breastfeeding or plan to breastfeed. Do not breastfeed during treatment
   with IMBRUVICA® and for 1 week after the last dose.

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works
and can cause side effects.

How should I take or give IMBRUVICA®?

 * Take or give IMBRUVICA® exactly as your healthcare provider tells you to take
   or give it.
 * Take or give IMBRUVICA® 1 time a day at about the same time each day.

IMBRUVICA® comes as capsules, tablets, and oral suspension.

 * If your healthcare provider prescribes IMBRUVICA® capsules or tablets:
   * Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
   * Do not open, break, or chew IMBRUVICA® capsules.
   * Do not cut, crush, or chew IMBRUVICA® tablets.
 * If your healthcare provider prescribes IMBRUVICA® oral suspension:
   * See the detailed Instructions for Use that comes with IMBRUVICA® oral
     suspension for information about the correct way to take or give a dose. If
     you have questions about how to take or give IMBRUVICA® oral suspension,
     talk to your healthcare provider.
   * Do not use if the carton seal is broken or missing.
 * If you miss a dose of IMBRUVICA®, take or give it as soon as you remember on
   the same day. Take or give the next dose of IMBRUVICA® at the regular time on
   the next day. Do not take or give extra doses of IMBRUVICA® to make up for a
   missed dose.
 * If you take too much IMBRUVICA®, call your healthcare provider or go to the
   nearest hospital emergency room right away.

What should I avoid while taking IMBRUVICA®?

 * You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges
   (often used in marmalades) during treatment with IMBRUVICA®. These products
   may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

 * Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA®
   and can also be serious and may lead to death. Your risk of bleeding may
   increase if you are also taking a blood thinner medicine. Tell your
   healthcare provider if you have any signs of bleeding, including: blood in
   your stools or black stools (looks like tar); pink or brown urine; unexpected
   bleeding, or bleeding that is severe or that you cannot control; vomit blood
   or vomit looks like coffee grounds; cough up blood or blood clots; increased
   bruising, or small red or purple spots on the skin; dizziness; weakness;
   confusion; change in your speech; or a headache that lasts a long time or
   severe headache.
 * Infections can happen during treatment with IMBRUVICA®. These infections can
   be serious and may lead to death. Tell your healthcare provider right away if
   you have fever, chills, weakness, confusion, or other signs or symptoms of an
   infection during treatment with IMBRUVICA®.
 * Heart problems. Serious heart rhythm problems (ventricular arrhythmias,
   atrial fibrillation, and atrial flutter), heart failure and death have
   happened in people treated with IMBRUVICA®, especially in people who have an
   infection, an increased risk for heart disease, or have had heart rhythm
   problems in the past. Your heart function will be checked before and during
   treatment with IMBRUVICA®. Tell your healthcare provider if you get any
   symptoms of heart problems, such as: feeling as if your heart is beating fast
   and irregular; lightheadedness; dizziness; shortness of breath; swelling of
   the feet, ankles, or legs; chest discomfort; or feeling faint. If you develop
   any of these symptoms, your healthcare provider may do tests to check your
   heart and may change your IMBRUVICA® dose.
 * High blood pressure (hypertension). New or worsening high blood pressure has
   happened in people treated with IMBRUVICA®. Your healthcare provider may
   start you on blood pressure medicine or change current medicines to treat
   your blood pressure.
 * Decrease in blood cell counts. Decreased blood counts (white blood cells,
   platelets, and red blood cells) are common with IMBRUVICA®, but can also be
   severe. Your healthcare provider should do monthly blood tests to check your
   blood counts.
 * Second primary cancers. New cancers have happened during treatment with
   IMBRUVICA®, including cancers of the skin or other organs.
 * Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer
   cells. TLS can cause kidney failure and the need for dialysis treatment,
   abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider
   may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies
(CLL/SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone,
and joint pain; low white blood cell count; rash; low red blood cell count
(anemia); bruising; and nausea.

The most common side effects of IMBRUVICA® in adults or children 1 year of age
and older with cGVHD include tiredness; low red blood cell count (anemia);
bruising; diarrhea; low platelet count; muscle, bone, and joint pain; fever;
muscle spasms; mouth sores (stomatitis); bleeding; nausea; stomach pain;
pneumonia; and headache.

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of
fluids during treatment with IMBRUVICA® to help reduce your risk of losing too
much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you
have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your healthcare
provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/PatientAccessSupport to learn more.

Please see the full Important Product Information.

USES

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® is a prescription medicine used to treat:

 * Adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
   (SLL).
 * Adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
   (SLL) with 17p deletion.
 * Adults with Waldenström's macroglobulinemia (WM).
 * Adults and children 1 year of age and older with chronic graft versus host
   disease (cGVHD) after failure of 1 or more lines of systemic therapy.

It is not known if IMBRUVICA® is safe and effective in children under 1 year of
age.

Please see the full Important Product Information.

Pharmacyclics, an AbbVie Company, may collect your personal data through your
online and offline interactions with us, including your contact, demographic,
geolocation, and health-related data. We may also collect your online usage data
automatically through cookies and similar technologies. We use this data for
several purposes, such as to provide you with and improve our programs,
services, and products, customize your experiences, and for research and
analytics. We retain your personal data for as long as necessary to fulfill
these purposes or to comply with our record retention obligations. We do not
sell your personal data but may use and disclose your personal data with
marketing and advertising partners to deliver you ads based on your interests
inferred from your activity across other unaffiliated sites and services
(“online targeted advertising”) and for website analytics. To opt out of the use
or disclosure of your personal data for online targeted advertising or for
website analytics, go to Your Privacy Choices on our website. For more
information on the personal data categories we collect, the purposes for their
collection, our disclosures to third parties, your data subject rights, and our
data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the
collection, use, and disclosure of my personal health data, as described in the
Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose
Personal Data section. My consent is required to process sensitive personal data
under certain privacy laws, and I have the right to withdraw my consent by
visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's
Orange Book (available at
https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).

© Pharmacyclics LLC 2024

© Janssen Biotech, Inc. 2024

03/24 US-IMBC-240093


 * Home
 * Prescribing Information
 * Important Side Effect Information
 * Legal Notice
 * Privacy Notice
 * Accessibility Statement
 * Cookies Settings
 * Your Privacy Choices
 * Contact Us
 * Site Map






AbbVie may use and disclose online usage data about you collected automatically
through online tracking technologies such as cookies, pixels, and web beacons
(collectively, “cookies”). We use this data for multiple purposes, including for
online targeted advertising (advertisements based on your interests inferred
from your activity across other unaffiliated sites and services) and website
analytics purposes, as well as to personalize content, save your preferences,
provide social media features, and track the site’s performance, as further
described in the"Cookies and similar tracking and data collection technologies"
section of our Privacy Notice. We retain this data for as long as necessary to
fulfill these purposes or as needed to comply with our record retention
obligations. We do not sell your data, but we may disclose it to our marketing
and advertising partners for purposes of online targeted advertising or for
website analytics purposes. To opt out of the use or disclosure of your
cookie-based personal data for online targeted advertising or for website
analytics purposes, or to otherwise manage your preferences, please click on
Cookie Settings below. For additional information on the categories of data we
collect, the purposes for their collection, disclosures to third parties, and
data retention, please visit ourPrivacy Notice.

Cookies Settings



PRIVACY PREFERENCE CENTER

You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.

Depending on the jurisdiction where you live, you may have the right to opt out
of the use and disclosure of your personal data for purposes of online targeted
advertising (advertisements based on your interests inferred from your activity
across other unaffiliated sites and services) or website analytics (to
understand website usage behavior and receive website analytics). To opt out of
the use and disclosure of your cookie-based personal data for these purposes,
you can toggle off “Functional” (for website analytics) and/or “Advertising”
(for online targeted advertising) below.

To opt out of the use and disclosure of your non-cookie-based information for
online targeted advertising purposes, please also click"Your Privacy Choices" on
our website.

Note that if we recognize your Global Privacy Control (GPC) as enabled, our
policy is to opt you out of the use or disclosure of your cookie-based personal
data for online targeted advertising and website analytics purposes for the
browser or device on which you have GPC enabled. However, unless you are logged
in to an AbbVie account that has the capability to link the personal data we
have about you to your browser or device, we cannot apply your GPC opt-out
request to your non-cookie based personal data because the connection between
your browser or device is not known to us. Thus, if you have GPC enabled, please
click"Your Privacy Choices" to opt out of the disclosure of your non-cookie
based personal data for these purposes.


MANAGE CONSENT PREFERENCES

REQUIRED COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.

View Vendor Details‎

FUNCTIONAL COOKIES

Functional Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.

View Vendor Details‎

ADVERTISING COOKIES

Advertising Cookies

These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.

View Vendor Details‎
Back Button


VENDORS LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Confirm My Choices